Description
Melanotan I (MT-1) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that increases melanin production in the skin. It was developed to stimulate eumelanin formation and has been investigated for pigmentation and photoprotection.
Unlike Melanotan II, MT-1 has been studied extensively in human clinical research, particularly for its effects on pigmentation and light sensitivity.
Product Information
Melanotan I, also known as NDP-α-MSH, interacts primarily with melanocortin receptors involved in melanin production. Human studies have demonstrated increased skin pigmentation and eumelanin production following MT-1 administration.
Research has also investigated MT-1 in combination with controlled UV exposure, where it produced stronger and more sustained tanning than UV exposure alone.
How Does Melanotan I Work?
MT-1 mimics α-MSH and activates melanocortin receptors on melanocytes, stimulating the production of eumelanin, the darker pigment responsible for skin tanning.
Melanotan I Benefits & Effects
Boosts Melanin Production
Melanotan I increases eumelanin production, resulting in measurable darkening of the skin. Human research has directly demonstrated increased eumelanin following MT-1 administration.
Promotes Skin Tanning
Clinical research has shown that MT-1 can produce noticeable skin pigmentation. In one human study, MT-1 produced increased tanning at several anatomical sites after a two-week dosing period.
Supports Photoprotection Research
Because eumelanin absorbs ultraviolet radiation, MT-1 has been investigated for its potential role in protecting skin against UV-related damage. Clinical research found fewer sunburn cells at irradiated sites in some MT-1-treated subjects.
Produces Longer-Lasting Pigmentation
Human research found that MT-1-enhanced tanning could persist longer than tanning produced by sunlight alone, making the compound particularly interesting in pigmentation research.
Supports Photosensitivity Research
MT-1 has also been studied in connection with disorders involving abnormal sensitivity to light. Its development eventually led to afamelanotide, a pharmaceutical melanocortin analogue used clinically for erythropoietic protoporphyria.




